Characteristic

Mean

Standard deviation

Age – year                                                          

33

±4.24

Weeks of pregnancy at screening

17.3

±9.01

Gestational Age at delivery (w)

39

±1.94                                                        

Table 1: Maternal characteristics at screening

CMV serology at pregnancy screening

 

No

%

IgM+, IgG+

17

89.5

IgM-, seroconversion                                        

2

10.5

Intervention

N

P (CMVIG)

6

NI (no intervention)

13

Total

19

P: prophylaxis (IGCMV), NI: no intervention,

Table 2: Pregnant women with primary CMV and Intervention submitted

 

CMVIG

No intervention

 

N

%

N

%

NB with PCR+ (urine)

2

33.3%

7

53.8%

NB with symptomatic congenital CMV

0

-

6

46.1%

Valganciclovir post natal as treatment

0

-

6*

46.1%

*1 symptomatic death

NB: New born; PCR: Polymerase Chain Reaction

Symptom

CMVIG

NI

Hearing loss or deficiency 

0

2

Hepatitis and/or liver / spleen enlargement

0

1

CNS alterations (calcifications, elevated CSF protein, and/or ventriculitis)

0

1

Anaemia and/or thrombocytopenia

0

2

Retinal Disease

0

2

 Other manifestations (petechiae and pericardial effusion)

0

1

NI: no intervention,